Patents by Inventor Joachim ALMQUIST

Joachim ALMQUIST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS
    Publication number: 20250002589
    Abstract: The disclosure relates to methods and compositions for the treatment of Cutaneous Lupus Erythematous (CLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
    Type: Application
    Filed: February 7, 2024
    Publication date: January 2, 2025
    Inventors: KATIE STREICHER, CATHARINA LINDHOLM, YEN LIN CHIA, RAJENDRA TUMMALA, LORIN ROSKOS, JOACHIM ALMQUIST, TOMAS ROUSE, JOAN MERRILL, VICTORIA WERTH
  • TREATMENT OF LUPUS NEPHRITIS WITH ANTI-TYPE I INF RECEPTOR ANTIBODY ANIFROLUMAB
    Publication number: 20250002590
    Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis (LN) with anti-type I IFN receptor inhibitor antibody Anifrolumab. Results of clinical trials with intravenous and subcutaneous administration of Anifrolumab. Identification of markers for LN and delivery devices and pre-filled syringe for administration of Anifrolumab.
    Type: Application
    Filed: April 22, 2022
    Publication date: January 2, 2025
    Inventors: CATHARINA LINDHOLM, YEN LIN CHIA, RAJENDRA TUMMALA, LORIN ROSKOS, JOACHIM ALMQUIST, TOMAS ROUSE, TEODORA TRASIEVA, WENDY WHITE, DOMINIC SINIBALDI, MADHU RAMASWAMY, PAUL NEWCOMBE
  • ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION
    Publication number: 20240400699
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: May 15, 2024
    Publication date: December 5, 2024
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE
  • DOSE
    Publication number: 20240360231
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: February 27, 2024
    Publication date: October 31, 2024
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE
  • Method of treating type 1 interferon (IFN)-mediated disease using a subcutaneous dosing regimen comprising anifrolumab
    Patent number: 12060429
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Grant
    Filed: April 21, 2023
    Date of Patent: August 13, 2024
    Assignee: AstraZeneca AB
    Inventors: Catharina Lindholm, Yen Lin Chia, Rajendra Tummala, Lorin Roskos, Joachim Almquist, Thomas Rouse
  • ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION
    Publication number: 20230365698
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 21, 2023
    Publication date: November 16, 2023
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Sr., Joachim ALMQUIST, Thomas ROUSE
  • TREATMENT OF LUPUS NEPHRITIS
    Publication number: 20220348669
    Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis. Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: November 3, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE, Teodora TRASIEVA, Wendy WHITE, Dominic SINIBALDI, Madhu RAMASWAMY, Paul NEWCOMBE
  • DOSE
    Publication number: 20220340669
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: October 27, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE